Q3 2023 Results - Reimagining Medicine

Company overview Innovation: Pipeline overview Financial review Financial performance Conclusions Novartis pipeline in registration Oncology Code Indication(s) Name Solid tumors LEE011 Kisqali® Mechanism CDK4/6 Inhibitor HR+/HER2- BC (adj) Hematology LNP023 iptacopan CFB inhibitor Immunology Code Name Mechanism AIN457 IGE025 Cosentyx® Xolair® IL17A inhibitor IgE inhibitor 1. Approved in EU. Paroxysmal nocturnal hemoglobinuria Indication(s) Hidradenitis suppurativa¹ Auto-injector Appendix Innovation: Clinical trials References Abbreviations INNOVATION 1 lead indications Lead indication 37 Investor Relations | Q3 2023 Results NOVARTIS | Reimagining Medicine

View entire presentation